BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Success of mRNA Rabies Vaccine Human Study Linked to Needle-Free Injection

  A key finding was that the use of needle-free injection demonstrated successful immunogenicity of the vaccine, while needle-syringe failed to induce an adequate antibody response.

  December 5, 2017

   · 

  2 min read
• Policy

  Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose

  damis intends to develop a naloxone injection product candidate utilizing the same patented Symject syringe drug delivery platform used in Adamis’ approved Symjepi product.

  December 5, 2017

   · 

  4 min read
• Biotech Beach

  Viking Therapeutics Announces Proposed Public Offering of Common Stock

  All of the shares to be sold in the offering are to be sold by Viking.

  December 5, 2017

   · 

  5 min read
• Biotech Beach

  Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results

  Arrowhead Pharmaceuticals Inc. announced that it will host a webcast and conference call on Tuesday, December 12, 2017, at 4:30 p.m. EST to discuss its financial results for the 2017 fiscal year ended September 30, 2017.

  December 5, 2017

   · 

  2 min read
• Policy

  Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application

  Clovis Oncology announced today that the FDA has accepted the company’s sNDA for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018.

  December 5, 2017

   · 

  8 min read
• Business

  Veeva Announces Fiscal 2018 Third Quarter Results

  Total revenues for the third quarter were $176.1 million, up from $142.8 million one year ago, an increase of 23% year-over-year.

  December 5, 2017

   · 

  24 min read
• TSX Defers Consideration of CanniMed Therapeutics Shareholder Rights Plan

  The TSX normally defers acceptance of shareholder rights plans adopted in response to a specific take-over bid.

  December 5, 2017

   · 

  2 min read
• Grünenthal Group Release: New Partnership for the Commercialization of Nucynta in the U.S. Territory

  Depomed executes its strategy to transform into a specialty pharmaceutical company with less focus on opioids.

  December 5, 2017

   · 

  3 min read
• Deals

  resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  resTORbio today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock.

  December 5, 2017

   · 

  1 min read
• 

  Deals

  LivaNova Pays $225M for San Diego’s ImThera Medical

  LivaNova will enter obstructive sleep apnea space, enhancing its portfolio of Neuromodulation treatments and therapies.

  December 5, 2017

   · 

  7 min read